Pixium wins UK nod for Iris II ‘bionic eye’ trial
French retinal implant maker Pixium Vision said today it won U.K. Medicines & Healthcare products Regulatory Agency approval to initiate a clinical trial of its Iris II bionic vision system designed to restore sight to patients with retinitis pigmentosa.
The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain lea...
Source: Mass Device - May 31, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news
US researchers investigate gene therapy treatment for X-linked retinitis pigmentosa
Researchers from the University of Pennsylvania have revealed a new animal study data, which analyses the efficacy of an investigational, adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 2, 2016 Category: Pharmaceuticals Source Type: news
QLT ends enrolment for natural history study in patients with RP and LCA
Canadian-based biotechnology company QLT has completed enrolment in its natural history study in subjects with Inherited Retinal Disease (IRD), phenotypically diagnosed with Retinitis Pigmentosa (RP), or Leber Congenital Amaurosis (LCA), due to under… (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2016 Category: Pharmaceuticals Source Type: news
MassDevice.com +5 | The top 5 medtech stories for March 30, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Trinity Medical picks up CasMed’s neonate disposables for $3m
Trinity Medical Devices said yesterday that it paid $3.35 million for CAS Medical System‘s line of neonatal intensive care disposables.
The deal includes a an ad...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Retina Implant Secures CE Mark for Wireless Subretinal Implant
CE certification enables commercialisation of Alpha AMS device to restore some useful vision in patients blinded by retinitis pigmentosa
REUTLINGEN, Germany, March 30, 2016 -- (Healthcare Sales & Marketing Network) -- Retina Implant AG, the leading dev... Devices, Ophthalmology, RegulatoryRetina Implant AG, Alpha AMS, Subretinal Implant, retinal implant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2016 Category: Pharmaceuticals Source Type: news
Retina Implant wins CE Mark for next-gen blindness implant
Retina Implant said today that it won CE Mark approval in the European Union for the latest iteration of its subretinal implant for patients blinded by retinitis pigmentosa.
The Alpha AMS is the next-generation version of the Alpha IMS, which won CE Mark approval back in July 2013. The Reutlingen, Germany-based company said the new device increases the number of pixels from 1,500 to 1,600, claiming the title for most electrodes of any neuroprosthetic implant.
“We are delighted by the news that our latest device has received the CE Mark. We believe that being able to provide physicians access to the Alpha AMS repr...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Optical/Ophthalmic Regulatory/Compliance CE Mark Retina Implant AG Source Type: news
Wayne State start-up, RetroSense, doses first patient in phase I/II RP clinical trial
(Wayne State University - Office of the Vice President for Research) A Wayne State University startup company announced today the first successful dosing of a patient in a clinical trial that is a major step forward for patients with vision challenges. RetroSense Therapeutics LLC, a privately held biopharmaceutical company, successfully dosed their first patient in the first clinical trial to evaluate the safety of RST-001. The study is titled 'Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in Patients with Retinitis Pigmentosa (RP).' (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2016 Category: Biology Source Type: news
MassDevice.com +3 | The top 3 medtech stories for March 2, 2016
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Retina Implant drums up $28m
Retina Implant said this week that it raised $28.2 million (€26 million) in private equity funding for its Alpha IMS device, which is designed to treat blind patients with retinitis pigmentosa.
The round including contributions from new and existing backers, the ...
Source: Mass Device - March 2, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news
Retina Implant drums up $28m
Retina Implant said this week that it raised $28.2 million (€26 million) in private equity funding for its Alpha IMS device, which is designed to treat blind patients with retinitis pigmentosa.
The round including contributions from new and existing backers, the Reutlingen, Germany-based company said. The proceeds are earmarked for new clinical centers and winning reimbursement in more markets for the Alpha IMS subretinal microchip.
“This re-investment is incredibly important to us as it solidifies our investors’ belief in our vision. This continued commitment will allow us to make great leaps forward to he...
Source: Mass Device - March 2, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Alcon Retina Implant AG WaveLight Laser Technologies Source Type: news
Pixium Vision touts 1st-in-human for Iris II retinal implant
French retinal implant maker Pixium Vision today announced the 1st implantation and successful activation of its Iris II epi-retinal implant designed for patients with vision loss as a result of retinitis pigmentosa.
The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain learns to interpret as visual signals.
“T...
Source: Mass Device - February 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news
Pixium Vision Implants IRIS(R) II, First Epi-Retinal Implant with 150 Electrodes
A major step forward in bionic vision for patients with retinitis pigmentosa
PARIS--(Healthcare Sales & Marketing Network)--Pixium Vision (FR0011950641 PIX) a company developing innovative bionic vision systems to allow patients who have lost their si... Devices, OphthalmologyPixium Vision, IRIS II, epi-retinal implant, retinitis pigmentosa, bionic vision (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 24, 2016 Category: Pharmaceuticals Source Type: news
Second Sight touts publication of 3-year Argus II study
This study validates the positive feedback we’ve been receiving from our recipients all along,” CEO Will McGuire said in prepared remarks.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
The post Second Sight touts publication of 3-year Argus II study appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
SAN FRANCISCO, February 5, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has... Biopharmaceuticals, Ophthalmology, FDAAmarantus Bioscience, retinitis pigmentosa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2016 Category: Pharmaceuticals Source Type: news
CRISPR used to repair blindness-causing genetic defect in patient-derived stem cells
Scientists have used a new gene-editing technology called CRISPR, to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 28, 2016 Category: Science Source Type: news
Edited stem cells offer hope of precision therapy for blindness
(University of Iowa Health Care) University of Iowa researchers have used the gene editing technology CRISPR/Cas9 to corrected a blindness-causing gene mutation in stem cells derived from a patient with X-linked Retinitis Pigmentosa. The result offers hope that eye diseases might one day be treated by personalized, precision medicine in which a patient's own cells are used to grow replacement tissue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2016 Category: Global & Universal Source Type: news
